Skip to main content
SpringerLink
Log in

Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Pleomorphic liposarcoma (PLPS) is a highly malignant subtype of liposarcoma. It is histologically characterized by the presence of pleomorphic lipoblasts and can be accompanied by morphological foci that demonstrate differentiation to other histological lineages. PLPS is rare and accounts for only 5% of all liposarcomas. PLPS exhibits poor prognosis; distant metastases develop in 30–50% of patients after curative surgical resection, tumor-associated mortality occurs in up to 50% of patients, and effective chemotherapies for PLPS have not been established. The histological accompaniment of other morphological foci is an important prognostic factor for PLPS, and the development of chemotherapies for PLPS considering the histological morphology is necessary. Patient-derived cancer cell lines are critical tools for basic and pre-clinical research to understand diseases and develop chemotherapies. However, only two PLPS-derived cell lines have been reported, and their donor tumor specimens did not histologically accompany morphological foci other than lipoblasts. Thus, there is a need to establish patient-derived PLPS cell lines from various histological morphologies. Here, we report a novel PLPS cell line from a tumor specimen that histologically accompanied pleomorphic and bone-forming foci, and named it NCC-PLPS2-C1. NCC-PLPS2-C1 cells demonstrated constant proliferation, spheroid formation, and invasion capability in vitro. Screening of antitumor agents in NCC-PLPS2-C1 cells showed that bortezomib, romidepsin, and trabectedin were effective against NCC-PLPS2-C1. In conclusion, we report the first PLPS cell line from a tumor specimen that was morphologically accompanied by pleomorphic and born-forming foci. We believe that NCC-PLPS2-C1 will be useful for the development of novel chemotherapies for PLPS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gjorgova-Gjeorgjievski S, Thway K, Dermawan JK, et al. Pleomorphic liposarcoma: a series of 120 cases with emphasis on morphologic variants. Am J Surg Pathol. 2022;46:1700–5.

    Article  Google Scholar 

  2. Gebhard S, Coindre JM, Michels JJ, et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2002;26:601–16.

    Article  Google Scholar 

  3. Lee ATJ, Thway K, Huang PH, Jones RL. Clinical and molecular spectrum of liposarcoma. J Clin Oncol. 2018;36:151–9.

    Article  CAS  Google Scholar 

  4. Wang L, Luo R, Xiong Z, Xu J, Fang D. Pleomorphic liposarcoma: an analysis of 6 case reports and literature review. Med (Baltim). 2018;97: e9986.

    Article  Google Scholar 

  5. Fritz B, Schubert F, Wrobel G, et al. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res. 2002;62:2993–8.

    CAS  Google Scholar 

  6. Idbaih A, Coindre JM, Derré J, et al. Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. Lab Invest. 2005;85:176–81.

    Article  CAS  Google Scholar 

  7. Rieker RJ, Joos S, Bartsch C, et al. Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas. Int J Cancer. 2002;99:68–73.

    Article  CAS  Google Scholar 

  8. Adachi T, Oda Y, Sakamoto A, et al. Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis. Oncol Rep. 2003;10:803–11.

    Google Scholar 

  9. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50.

    Article  CAS  Google Scholar 

  10. Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346:1480–6.

    Article  CAS  Google Scholar 

  11. Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014;74:2377–84.

    Article  CAS  Google Scholar 

  12. Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2016;14:3–13.

    Article  CAS  Google Scholar 

  13. Warren A, Chen Y, Jones A, et al. Global computational alignment of tumor and cell line transcriptional profiles. Nat Commun. 2021;12:22.

    Article  CAS  Google Scholar 

  14. Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25–38.

    Article  Google Scholar 

  15. Hideyuki T, Yoko T, Daisuke M, Miharu K, Tohru M, Hiroshi M. Cell line individualization by str multiplex system in the cell bank found cross-contamination between ECV304 and EJ-1/T24. Tissue Cult Res Commun. 1999;18:329–38.

    Google Scholar 

  16. Masters JR, Thomson JA, Daly-Burns B, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA. 2001;98:8012–7.

    Article  CAS  Google Scholar 

  17. Drexler HG, Dirks WG, MacLeod RA, Uphoff CC. False and mycoplasma-contaminated leukemia-lymphoma cell lines: time for a reappraisal. Int J Cancer. 2017;140:1209–14.

    Article  CAS  Google Scholar 

  18. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47:D941–7.

    Article  CAS  Google Scholar 

  19. Sunami K, Ichikawa H, Kubo T, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci. 2019;110:1480–90.

    Article  CAS  Google Scholar 

  20. Billiau A, Edy VG, Heremans H, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977;12:11–5.

    Article  CAS  Google Scholar 

  21. Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope. 2001;111:696–701.

    Article  CAS  Google Scholar 

  22. Schöffski P. Established and experimental systemic treatment options for advanced liposarcoma. Oncol Res Treat. 2022;45:525–43.

    Article  Google Scholar 

  23. Wabitsch M, Brüderlein S, Melzner I, Braun M, Mechtersheimer G, Möller P. LiSa-2, a novel human liposarcoma cell line with a high capacity for terminal adipose differentiation. Int J Cancer. 2000;88:889–94.

    Article  CAS  Google Scholar 

  24. Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma. Hum Cell. 2021;34:688–97.

    Article  CAS  Google Scholar 

  25. Gao P, Seebacher NA, Hornicek F, Guo Z, Duan Z. Advances in sarcoma gene mutations and therapeutic targets. Cancer Treat Rev. 2018;62:98–109.

    Article  CAS  Google Scholar 

  26. Czarnecka AM, Synoradzki K, Firlej W, et al. Molecular biology of osteosarcoma. Cancers (Basel). 2020;12:2130.

    Article  CAS  Google Scholar 

  27. Liu J, Zhao R, Jiang X, Li Z, Zhang B. Progress on the application of bortezomib and bortezomib-based nanoformulations. Biomolecules. 2021;12:51.

    Article  Google Scholar 

  28. Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18:1414.

    Article  Google Scholar 

  29. Zarin DA, Fain KM, Dobbins HD, Tse T, Williams RJ. 10-Year update on study results submitted to ClinicalTrials.gov. N Engl J Med. 2019;381:1966–74.

    Article  Google Scholar 

  30. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34:786–93.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Drs. E. Kobayashi, K. Ogura, S. Osaki, S. Fukushima, K. Sato, S. Ishihara, Y. Toda (Department of Musculoskeletal Oncology, the National Cancer Center Hospital) for sampling tumor tissue specimens from surgically resected materials. We also appreciate the technical support provided by Mrs. Y. Shiotani, Mr. N. Uchiya, and Dr. T. Imai (Central Animal Division, National Cancer Center Research Institute). We would like to thank Editage (www.editage.jp) for providing English language editing services and for their constructive comments on this manuscript. This study was technically assisted by the Fundamental Innovative Oncology Core of the National Cancer Center.

Funding

This research was supported by the Japan Agency for Medical Research and Development (grant number: 20ck0106537h0003).

Author information

Authors and Affiliations

  1. Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Taro Akiyama, Yuki Yoshimatsu, Rei Noguchi, Yooksil Sin, Julia Osaki, Yuki Adachi, Takuya Ono & Tadashi Kondo

  2. Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, 260-8670, Japan

    Taro Akiyama, Ryuto Tsuchiya & Seiji Ohtori

  3. Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Ryuto Tsuchiya, Chiaki Sato, Shintaro Iwata & Akira Kawai

  4. Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Naoki Kojima & Akihiko Yoshida

  5. Department of Patient-Derived Cancer Model, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan

    Yuki Yoshimatsu

Authors
  1. Taro Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuki Yoshimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rei Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yooksil Sin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Julia Osaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuki Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takuya Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ryuto Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chiaki Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shintaro Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Naoki Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Akihiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Seiji Ohtori
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Akira Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tadashi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadashi Kondo.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethics approval

The ethical committee of the National Cancer Center approved the use of clinical materials for this study (approval number 2004-050). Animal experiments were conducted in compliance with the guidelines of the Institute for Laboratory Animal Research, National Cancer Center Research Institute.

Informed consent

Written informed consent was provided by the patient.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

13577_2022_828_MOESM1_ESM.tiff

Supplementary Fig. 1 Short tandem repeat patterns of NCC-PLPS2-C1 cells and original tumor tissue. (A) Short tandem repeat patterns of NCC-PLPS2-C1 cells (p20) and (B) short tandem repeat patterns of original tumor tissue of NCC-PLPS2-C1 (TIFF 3922 kb)

Supplementary file1 (XLSX 10 kb)

Supplementary file2 (XLSX 11 kb)

Supplementary file3 (XLSX 22 kb)

Supplementary file4 (XLSX 13 kb)

Supplementary file5 (XLSX 25 kb)

Supplementary file6 (XLSX 12 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akiyama, T., Yoshimatsu, Y., Noguchi, R. et al. Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma. Human Cell 36, 468–475 (2023). https://doi.org/10.1007/s13577-022-00828-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-022-00828-9

Keywords

Search

Navigation